Pharmacomechanical thrombectomy of iliofemoral deep vein thrombosis is associated with a low incidence of post‐thrombotic syndrome and perioperative complications

Abstract

AbstractBackgroundIliofemoral deep venous thrombosis (IFDVT) is associated with an incidence of post‐thrombotic syndrome (PTS) of up to 50%. PTS is associated with high morbidity, impaired quality of life and a significant economic burden. The aim of the current study was to assess the impact of a single session pharmacomechanical thrombectomy (PMT), dedicated venous stents and a risk mitigation protocol on the rate of PTS.MethodsBetween 2015 and 2022, patients presenting with acute or subacute IFDVT treated with the same protocol of single session PMT, dedicated venous stents, and risk‐mitigation measures were included. Procedural success rate, complications, stent patency and incidence of PTS were determined.ResultsOf 60 patients (58 ± 19 years; 65% male), the procedural success rate was 93%, with 7% of patients experiencing complications but no long‐term sequelae or mortality. Most (n = 52; 87%) patients were stented, including 46% across the inguinal ligament. At 3 months post‐procedure, primary, assisted primary and secondary stent patency rates were 89%, 93% and 98%, respectively, with no loss of patency or re‐interventions after that. At latest follow‐up of a median 48 months (n = 32), stent patency rate was 97%, with only three patients (9%) experiencing symptoms of PTS.ConclusionSingle session PMT, dedicated venous stents and a risk‐mitigation protocol results in high success rate, excellent long‐term stent patency and low incidence of PTS without compromising safety. These results support early intervention for iliofemoral DVT.